WuXi Biologics (Cayman) Inc. (2269.HK) HKSE

Currency In HKD

AD

Valuation

Market Cap119.42B
Enterprise Value113.3B
P/E Ratio36.68
PEG Ratio0.78
Price/Sales Ratio8.3
Price/Book Ratio3.89
Enterprise/Revenue8.02
Enterprise/EBITDA22.05

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterDecember 31, 2025

Profitability

Profit Margin0.23
Operating Margin0.3
AD

Management Effectiveness

Return On Assets0.08
Return On Equity0.11

Income Statement

Revenue21.79B
Revenue/Share5.17
Gross Profit10.02B
EBITDA7.92B
Net Income4.91B
Diluted EPS1.16

Balance Sheet

Total Cash15.74B
Total Cash/Share3.73
Total Debt3.11B
Total Debt/Equity0.07
Current Ratio3.14
Book Value Per Share12.58

Price History

52-Week Change62.84
52-Week High51.55
52-Week Low28.48
Moving Average 50 Days38.59
Moving Average 200 Days35.83

Statistics

Average Volume34.93M
Shares Outstanding4.14B
% Held by Institutions0.23

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor3:1
Last Split DateNovember 16, 2020
AD